Mitoxantrone Hydrochloride Liposome

Phase 3Small molecule

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Mitoxantrone Hydrochloride Liposome is one of 296 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

295

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaNot yet recruiting

LymphomaUnknown status

Diffuse Large B-Cell LymphomaUnknown status

TreatmentRecruiting

Refractory Acute Myeloid LeukemiaNot yet recruiting

Acute Myeloid Leukemia (AML)Not yet recruiting

PTCLRecruiting

Nasopharyngeal CancerNot yet recruiting

Induction TherapyRecruiting

Relapsed/refractoryRecruiting

Nasopharyngeal CarcinomaPhase 3

Not yet recruiting

LymphomaPhase 2

Unknown status

Diffuse Large B-Cell LymphomaPhase 2

Unknown status

TreatmentPhase 2

Recruiting

Refractory Acute Myeloid LeukemiaPhase 2

Not yet recruiting

Acute Myeloid Leukemia (AML)Phase 3

Not yet recruiting

PTCLPhase 2

Recruiting

Nasopharyngeal CancerPhase 2

Not yet recruiting

Induction TherapyPhase 2

Recruiting

Relapsed/refractoryPhase 2

Recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

370 competitors in Lymphoma

#DrugCompanyPhaseTrials

Mitoxantrone Hydrochloride Liposome

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3

5 2

Zofran

Novartis

Preclinical

2 3

Norvir

AbbVie

Preclinical

1 4

Cabenuva

GSK

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Nasopharyngeal Cancer

NCT06892431

Phase 2Recruiting

Relapsed/refractory

NCT06489808

Q3 2027

Phase 1/2Recruiting

Diffuse Large B-Cell Lymphoma

NCT06594640

Phase 3Not yet recruiting

Nasopharyngeal Carcinoma

NCT05717764

Phase 2Recruiting

Recurrent or Metastatic NPC

NCT06472713

Q4 2027

Phase 2Recruiting

Treatment

NCT06447090

Clinical

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma6 trials

R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT06594640·108 enrolled

R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT05777369·30 enrolled

Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT05875428·104 enrolled

Show 3 more trials

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

Not yet recruiting·TThe First Hospital of Jilin University·N/A·NCT05990985·20 enrolled

R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT05784987·60 enrolled

Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Unknown status·JJianfeng Zhou·Phase 2·NCT05575973·55 enrolled

Lymphoma5 trials

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Recruiting·SSun Yat-sen University·Phase 1/2·NCT07093710·101 enrolled

A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT03776279·106 enrolled

Clinical Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Recurrent/Refractory Lymphoma Subjects

Completed· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT05173545·24 enrolled

Show 2 more trials

A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma

Unknown status·SSun Yat-sen University·Phase 1/2·NCT05527275·78 enrolled

Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors

Active, not recruiting·SSun Yat-sen University·Phase 1·NCT05620862·68 enrolled

Treatment3 trials

Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT06434662·34 enrolled

Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT06621212·72 enrolled

VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06447090·30 enrolled

Breast Cancer3 trials

Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer

Unknown status·—·N/A·NCT06156761·24 enrolled

A Study of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast Cancer

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT02596373·60 enrolled

A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer

Terminated· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT04927481·28 enrolled

Lip2 trials

Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection

Completed· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT02043756·20 enrolled

Phase I Study of Mitoxantrone Hydrochloride Liposome Injection

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT02131688·30 enrolled

22 more indications

Acute Myeloid Leukemia2 trials

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

Terminated· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1/2·NCT05345938·1 enrolled

A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1/2·NCT05100303·58 enrolled

Nasopharyngeal Carcinoma2 trials

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Recruiting·MMing-Yuan Chen·Phase 2·NCT07070479·208 enrolled

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment

Not yet recruiting·CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.·Phase 3·NCT05717764·500 enrolled

Relapsed/Refractory2 trials

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

Active, not recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 3·NCT04668690·193 enrolled

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06489808·89 enrolled

Patients With Advanced Solid Tumors2 trials

A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT05344742·116 enrolled

A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors

Completed· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT04921878·29 enrolled

Newly Diagnosed2 trials

Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT06621199·42 enrolled

Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML

Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT07486479·204 enrolled

Induction Therapy1 trial

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

Recruiting·—·Phase 2·NCT06221683·500 enrolled

Malignant Tumor1 trial

A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor

Suspended· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT05089461·120 enrolled

Infusion1 trial

A Study of Mitoxantrone Hydrochloride Liposome Infusion

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1/2·NCT02856685·60 enrolled

Nasopharyngeal Cancer1 trial

JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 2·NCT06892431·150 enrolled

Recurrent or Metastatic NPC1 trial

Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC

Recruiting·MMing-Yuan Chen·Phase 2·NCT06472713·32 enrolled

Ovarian Cancer1 trial

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer

Terminated· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT04718376·56 enrolled

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT04719065·90 enrolled

Metastatic Head and Neck Cancer1 trial

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers

Completed· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT04902027·45 enrolled

Soft Tissue Sarcoma1 trial

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma

Terminated· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT04900766·31 enrolled

Pancreatic Cancer1 trial

A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT05100329·38 enrolled

Gastric Carcinoma1 trial

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma

Terminated· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT04718402·21 enrolled

Multiple Sclerosis1 trial

A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis

Withdrawn·CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.·Phase 2·NCT05496894

PTCL1 trial

Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL

Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT07372352·26 enrolled

Refractory Acute Myeloid Leukemia1 trial

A Clinical Study Of Mitoxantrone Hydrochloride Liposome Plus Cladribine Combined With Sotorasib In Patients With Relapsed And Refractory Acute Myeloid Leukemia

Not yet recruiting·TThe Affiliated People's Hospital of Ningbo University·Phase 2·NCT07874737·20 enrolled

Acute Myeloid Leukemia (AML)1 trial

A Prospective, Multicenter, Randomized Controlled Clinical Study of Mitoxantrone Hydrochloride Liposome, Subcutaneous Cytarabine and G-CSF Combined With Venetoclax Versus Azacitidine Combined With Venetoclax in the Treatment of MDS-IB2 and Newly Diagnosed Adult Secondary or Elderly AML

Not yet recruiting·RRuijin Hospital·Phase 3·NCT07735117·168 enrolled

Sources

References

[1]
ClinicalTrials.gov — 46 trial records for Mitoxantrone Hydrochloride Liposome. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mitoxantrone Hydrochloride Liposome compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mitoxantrone Hydrochloride Liposome. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSPC ZhongQi Pharmaceutical Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Mitoxantrone Hydrochloride Liposome

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma6 trials

Lymphoma5 trials

Treatment3 trials

Breast Cancer3 trials

Lip2 trials

Acute Myeloid Leukemia2 trials

Nasopharyngeal Carcinoma2 trials

Relapsed/Refractory2 trials

Patients With Advanced Solid Tumors2 trials

Newly Diagnosed2 trials

Induction Therapy1 trial

Malignant Tumor1 trial

Infusion1 trial

Nasopharyngeal Cancer1 trial

Recurrent or Metastatic NPC1 trial

Ovarian Cancer1 trial

Neuromyelitis Optica1 trial

Dexamethasone1 trial

Advanced Solid Tumor1 trial

Metastatic Head and Neck Cancer1 trial

Soft Tissue Sarcoma1 trial

Pancreatic Cancer1 trial

Gastric Carcinoma1 trial

Multiple Sclerosis1 trial

PTCL1 trial

Refractory Acute Myeloid Leukemia1 trial

Acute Myeloid Leukemia (AML)1 trial

References

Drug Info

Quick Facts

Related News